Cost-Effectiveness Analysis of Sacubitril/Valsartan for the Treatment of Heart Failure with Reduced Ejection Fraction in the United States

Cost-Effectiveness Analysis of Sacubitril/Valsartan in Chronic Heart Failure with Reduced Ejection Fraction in Spain

Value in Health ◽

10.1016/j.jval.2016.09.1749 ◽

2016 ◽

Vol 19 (7) ◽

pp. A650

Author(s):

C Lacasa ◽

M Obradors ◽

M Figueras ◽

F Pérez-Alcántara ◽

M Brosa

Keyword(s):

Heart Failure ◽

Cost Effectiveness ◽

Chronic Heart Failure ◽

Ejection Fraction ◽

Cost-Effectiveness Analysis of Sacubitril/Valsartan Compared With Standard Acei Therapies For Heart Failure Patients With Reduced Ejection Fraction In Taiwan

Value in Health ◽

10.1016/j.jval.2017.08.1239 ◽

2017 ◽

Vol 20 (9) ◽

pp. A617

Author(s):

C Fann ◽

S Chen

Keyword(s):

Heart Failure ◽

Cost Effectiveness ◽

Ejection Fraction ◽

Heart Failure Patients ◽

Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction

JAMA Cardiology ◽

10.1001/jamacardio.2016.1747 ◽

2016 ◽

Vol 1 (6) ◽

pp. 666 ◽

Cited By ~ 59

Author(s):

Thomas A. Gaziano ◽

Gregg C. Fonarow ◽

Brian Claggett ◽

Wing W. Chan ◽

Celine Deschaseaux-Voinet ◽

...

Keyword(s):

Heart Failure ◽

Cost Effectiveness ◽

Ejection Fraction ◽

Effectiveness Analysis ◽

Patients With Heart Failure

A COST-EFFECTIVENESS ANALYSIS IN THE US OF LCZ696 (SACUBITRIL/VALSARTAN) VERSUS RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITION FOR HEART FAILURE PATIENTS WITH REDUCED EJECTION FRACTION

Journal of the American College of Cardiology ◽

10.1016/s0735-1097(16)31303-1 ◽

2016 ◽

Vol 67 (13) ◽

pp. 1302 ◽

Cited By ~ 1

Author(s):

Thomas A. Gaziano ◽

Gregg Fonarow ◽

Brian Claggett ◽

Milton Packer ◽

Michael Zile ◽

...

Keyword(s):

Heart Failure ◽

Cost Effectiveness ◽

Ejection Fraction ◽

Renin Angiotensin Aldosterone System ◽

Renin Angiotensin ◽

Heart Failure Patients ◽

Effectiveness Analysis ◽

The Us

Cost-Effectiveness Analysis of the Adjunctive Therapy of Ivabradine for the Treatment of Heart Failure with Reduced Ejection Fraction

ClinicoEconomics and Outcomes Research ◽

10.2147/ceor.s226568 ◽

2019 ◽

Vol Volume 11 ◽

pp. 767-777 ◽

Cited By ~ 2

Author(s):

Rungroj Krittayaphong ◽

Jirawit Yadee ◽

Unchalee Permsuwan

Keyword(s):

Heart Failure ◽

Cost Effectiveness ◽

Ejection Fraction ◽

Adjunctive Therapy ◽

Cost-Effectiveness Analysis of Sacubitril-Valsartan Compared with Enalapril in Patients with Heart Failure with Reduced Ejection Fraction in Thailand

American Journal of Cardiovascular Drugs ◽

10.1007/s40256-018-0288-x ◽

2018 ◽

Vol 18 (5) ◽

pp. 405-413 ◽

Cited By ~ 5

Author(s):

Rungroj Krittayaphong ◽

Unchalee Permsuwan

Keyword(s):

Heart Failure ◽

Cost Effectiveness ◽

Ejection Fraction ◽

Effectiveness Analysis ◽

Patients With Heart Failure

Cost-effectiveness analysis of dapagliflozin in addition to standard therapy in heart failure with reduced ejection fraction: A Qatari healthcare perspective

Journal of Emergency Medicine Trauma and Acute Care ◽

10.5339/jemtac.2022.qhc.62 ◽

2021 ◽

Vol 2022 (1) ◽

Author(s):

Daoud Al-Badriyeh ◽

Salma Chbib ◽

Palli Valapila Abdulrouf ◽

Moza Al Hail ◽

Wessam El Kassem ◽

...

Keyword(s):

Heart Failure ◽

Cost Effectiveness ◽

Ejection Fraction ◽

Standard Therapy ◽

Healthcare Perspective ◽

Faculty Opinions recommendation of Tranexamic acid in the routine treatment of postpartum hemorrhage in the United States: a cost-effectiveness analysis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.736028641.793572950 ◽

2020 ◽

Author(s):

John Svigos

Keyword(s):

United States ◽

Cost Effectiveness ◽

Tranexamic Acid ◽

Postpartum Hemorrhage ◽

The United States ◽

Routine Treatment ◽

PND5 Cost-Effectiveness Analysis of Newborn Screening for Spinal Muscular Atrophy in the United States

Value in Health Regional Issues ◽

10.1016/j.vhri.2020.07.393 ◽

2020 ◽

Vol 22 ◽

pp. S75

Author(s):

R. Arjunji ◽

J. Zhou ◽

A. Patel ◽

M.L. Edwards ◽

M. Harvey ◽

...

Keyword(s):

United States ◽

Cost Effectiveness ◽

Spinal Muscular Atrophy ◽

Newborn Screening ◽

Muscular Atrophy ◽

The United States ◽

Cost-Effectiveness Analysis of rFVIIIFc Versus Contemporary rFVIII Treatments for Patients with Severe Hemophilia A Without Inhibitors in the United States

PharmacoEconomics - Open ◽

10.1007/s41669-021-00283-6 ◽

2021 ◽

Author(s):

Ash Bullement ◽

Emma S. Knowles ◽

Pronabesh DasMahapatra ◽

Talaha Ali ◽

Ron Preblick

Keyword(s):

United States ◽

Cost Effectiveness ◽

Hemophilia A ◽

The United States ◽

Severe Hemophilia ◽